Menéndez Sergio, Khan Zeb, Coomber David W, Lane David P, Higgins Maureen, Koufali Maria M, Lain Sonia
Department of Surgery and Molecular Oncology, the University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, Scotland, United Kingdom.
J Biol Chem. 2003 May 23;278(21):18720-9. doi: 10.1074/jbc.M211007200. Epub 2003 Feb 11.
The tumor suppressor ARF plays an important role as an inhibitor of the Mdm2-mediated degradation of p53. Here we demonstrate that human ARF (p14ARF) can form homo-oligomers. The stability of the oligomers is favored by oxidizing agents in a reversible fashion and involves all three cysteine residues in p14ARF. Furthermore, the effect of p14ARF in clonogenic assays is moderately but reproducibly increased by the mutation of its cysteine residues. We also observed that altering the amino terminus of p14ARF resulted in the appearance of remarkably stable oligomers. This indicates that the amino terminus of p14ARF interferes with the ability of the protein to form multimeric complexes. These observations suggest that p14ARF activity may be linked to its oligomerization status and sensitive to the redox status of the cell.
肿瘤抑制因子ARF作为Mdm2介导的p53降解的抑制剂发挥着重要作用。在此我们证明,人ARF(p14ARF)能够形成同型寡聚体。氧化剂以可逆的方式促进寡聚体的稳定性,且该过程涉及p14ARF中的所有三个半胱氨酸残基。此外,p14ARF的半胱氨酸残基发生突变后,其在克隆形成试验中的作用虽适度但可重复性地增强。我们还观察到,改变p14ARF的氨基末端会导致出现非常稳定的寡聚体。这表明p14ARF的氨基末端会干扰该蛋白形成多聚体复合物的能力。这些观察结果表明,p14ARF的活性可能与其寡聚化状态相关,并对细胞的氧化还原状态敏感。